Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study

Autor: Paola Colombo, Silvio Klugmann, Flavio Ribichini, Leonardo De Luca, Maurizio Ferrario Ormezzano, Alessandro Petrolini, Corrado Vassanelli, Alberto Barioli, Giuseppe Tarantini, Paolo Calabrò, Fabrizio Tomai, Alberto Forni, Giuseppe Faggian, Renato Bianchi, Michele Pighi, Marco Valgimigli, Marco Ferlini, Bruno Loi
Přispěvatelé: Pighi, Michele, Tomai, Fabrizio, Petrolini, Alessandro, de Luca, Leonardo, Tarantini, Giuseppe, Barioli, Alberto, Colombo, Paola, Klugmann, Silvio, Ferlini, Marco, Ormezzano, Maurizio Ferrario, Loi, Bruno, Calabro', Paolo, Bianchi, Renato Maria, Faggian, Giuseppe, Forni, Alberto, Vassanelli, Corrado, Valgimigli, Marco, Ribichini, Flavio
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Biocompatible
Cardiac Catheterization
Time Factors
medicine.medical_treatment
Pharmaceutical Science
Pilot Projects
Coronary Artery Disease
030204 cardiovascular system & hematology
Coronary artery disease
0302 clinical medicine
Clinical Protocols
Absorbable Implants
030212 general & internal medicine
Prospective Studies
Prospective cohort study
Genetics (clinical)
Cardiac catheterization
Heart transplantation
Allografts
Everolimus-eluting bioresorbable vascular scaffold
Treatment Outcome
Italy
Research Design
cardiovascular system
Cardiology
Molecular Medicine
Heart transplant
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
Context (language use)
Prosthesis Design
03 medical and health sciences
Genetic
Internal medicine
Genetics
medicine
Humans
Everolimus
Cardiac allograft vasculopathy
3003
business.industry
Cardiovascular Agents
Heart Transplantation
Coated Materials
Biocompatible
Coated Materials
medicine.disease
Surgery
Concomitant
Cardiovascular agent
business
Popis: Cardiac allograft vasculopathy (CAV) is a form of accelerated atherosclerosis, which represents the leading cause of late morbidity and mortality after heart transplantation. The recent bioresorbable vascular scaffold (BVS) technology represents a potential novel therapeutic tool, in the context of CAV, by allowing transient scaffolding and concomitant vessel healing. Eligible subjects will be treated by using the Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA), and evaluated at pre-determined time points, up to 3 years since the index procedure. Both clinical and imaging data will be collected in dedicated case report forms (CRF). All imaging data will be analyzed in an independent core laboratory. The primary aim of the study is to evaluate the angiographic performance at 1 year of second-generation Absorb BVS, in heart transplant recipients affected by CAV.
Databáze: OpenAIRE
Externí odkaz: